Rozanolixizumab is being developed for the treatment of various IgG autoantibody-driven autoimmune diseases by promoting the clearance of pathogenic IgG autoantibodies. Its intended therapeutic indications include generalized myasthenia gravis (gMG), primary immune thrombocytopenia (ITP), myelin oligodendrocyte glycoprotein immunoglobulin G antibody-associated disease (MOGAD), autoimmune encephalitis (AIE), and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).